advertising
-
1
National Center for Health Statistics: Health, United States, 2006, With Chartbook on Trends in the Health of Americans, National Center for Health Statistics, Hyattsville, MD. ,2006. .
-
2
Littleton J, Barron S, Prendergast M, et al: Smoking kills (alcoholics)! Shouldn’t we do something about it? Alcohol Alcohol 42: 167. ,2007. .
-
3
Grucza RA, Bierut LJ: Cigarette smoking and risk for alcohol use disorders among adolescent drinkers. .Alcohol Clin Exp Res 30::2046. ,2006. .
-
4
Bauer LA: “Clinical Pharmacokinetics and Pharmacodynamics,” in Pharmacotherapy: A Pathophysiologic Approach, ed by JT Dipro, p 21, Appleton & Lange, Stamford, CT. ,1999. .
-
5
Hansten PD, Horn JR: “Drug Interaction Mechanisms: Enzyme Induction,” in Hansten and Horn’s Drug Interactions Analysis and Management, p PM1, Facts and Comparisons, St Louis. ,2003. .
-
6
Benet LZ, Kroetz DL, Sheiner LB: “Pharmacokinetics: The Dynamics of Drug Absorption, Distribution, and Elimination,” in Goodman and Gilman’s The Pharmacological Basis of Therapeutics, ed by JG Hardman, LE Limbird, p 3, McGraw-Hill, New York. ,1996. .
-
7
Leucuta SE, Vlase L: Pharmacokinetics and metabolic drug interactions. .Curr Clin Pharmacol 1::5. ,2006. .
-
8
Nelson DR, Koymans L, Kamataki T, et al: P450 superfamily: update on new sequences, gene mapping, accession numbers and nomenclature. .Pharmacogenetics 6::1. ,1996. .
-
9
Streetman DS: Metabolic differences and pharmacogenetics: implications for anesthesia. .Anesthesia Today 14::12. ,2004. .
-
10
Koch I, Weil R, Wolbold R, et al: Interindividual variability and tissue-specificity in the expression of cytochrome P450 3A mRNA. .Drug Metab Dispos 30::1108. ,2002. .
-
11
Horn JR, Hanseten P: Potential drug interactions in smokers and quitters. .Pharmacy Times 73::56. ,2007. .
-
12
Schein JR: Cigarette smoking and clinically significant drug interaction. .Ann Pharmacother 29::1139. ,1995. .
-
13
Zevin S, Benowitz NL: Drug interactions with tobacco smoking: an update. .Clin Pharmacokinet 36::425. ,1999. .
-
14
Kroon LA: Drug interactions and smoking: raising awareness for acute and critical care providers. .Crit Care Nurs Clin North Am 18::53. ,2006. .
-
15
McKinnon RA, Evans AM: Cytochrome P450: clinically significant drug interactions. .Aust J Hosp Pharm 30::146. ,2000. .
-
16
Guengerich FP, Shimada T, Yun C, et al: Interactions of ingested food, beverage, and tobacco components involving human cytochrome P450 1A2, 2A6, 2E1, and 3A4 enzymes. .Environ Health Perspect 102::49. ,1994. .
-
17
Huet PM, Leloier J: Effects of smoking and chronic hepatitis B on lidocaine and indocyanine green kinetics. .Clin Pharmacol Ther 28::208. ,1980. .
-
18
Gordis E: Alcohol alert: alcohol-medication interactions, National Institute on Alcohol Abuse and Alcoholism No. 27 PH 355 January 1995. Available at: http://pubs.niaaa.nih.gov/publications/aa27.htm. Accessed July 16. ,2007. .
-
19
Guram MS, Howden CW, Holt S: Alcohol and drug interactions. .Pract Gastroenterol 16::47. ,1992. .
-
20
Dorian P, Sellers EM, Reed KL, et al: Amitriptyline and ethanol: pharmacokinetic and pharmacodynamic interaction. .Eur J Clin Pharmacol 25::325. ,1983. .
-
21
Balant-Gorgia AE, Gay M, Gex-Fabry M, et al: Persistent impairment of clomipramine demethylation in recently detoxified alcoholic patients. .Ther Drug Monit 14::119. ,1992. .
-
22
Lamb E: Top 200 prescription drugs of 2006. .Pharmacy Times 73::34. ,2007. .
-
23
Murray L: Physician’s Desk Reference, 61st Ed, Thompson Medical Economics, Montvale, NJ. ,2007. .
-
24
Wickersham RM: Drug Facts and Comparisons 2007, Wolters Kluwer Health, St Louis. ,2007. .
-
25
McEvoy GK: AHFS Drug Information 2007, American Society of Health-System Pharmacists, Bethesda, MD. ,2007. .
-
26
Centers for Disease Control and Prevention: Fact sheet: adult cigarette smoking in the United States: current estimates. Available at: http://www.cdc.gov/tobacco/data_statistics/fact_sheets/adult_data/adult_cig_smoking.htm. Accessed July 14. ,2007. .
An Appraisal of Potential Drug Interactions in Cigarette Smokers and Alcohol Drinkers
Search for other papers by Robert G. Smith in
Current site
Google Scholar
PubMed
Background: Many health-care providers may overlook or be unaware of most drug-to-drug interactions. Recognizing the existence of drug interactions with cigarette smoking and alcohol ingestion can empower a clinician with knowledge to avoid dangerous interactions that may result in hazardous, negative patient outcomes. Cigarette smoking and alcohol use can reduce the efficiency of certain drugs or make drug therapy more unpredictable.
Methods: This review offers the physician information regarding prescription drug interactions with cigarette smoking and alcohol use. First, mechanisms found in the medical literature of potential drug interactions in cigarette smokers and alcohol drinkers are presented. Second, the 100 most frequently prescribed medications in 2006 are reviewed regarding cigarette smoking effects and alcohol effects as cited in the medical literature. Lastly, a table of these 100 medications and any reported effects of cigarette smoking or alcohol consumption on each drug is provided.
Results: The actual number of different medications reviewed was 78. Drug interactions resulting from the effects of cigarette smoking occurred with 33.3% of the drugs (n = 26), and drug interactions resulting from the effects of alcohol consumption occurred with 76.9% of the drugs (n = 60). Finally, resource information regarding smoking cessation and alcohol abuse recovery is summarized so that physicians may empower their patients to avoid potential drug-interaction events.
Conclusions: Cigarette smoke and alcohol may interact with medications through pharmacokinetic or pharmacodynamic mechanisms. Engaging in both of these social activities can reduce the efficiency of certain drugs or can make drug therapy unpredictable. This review offers the health-care provider information regarding potential prescription drug interactions. Empowered with this information, clinicians may assist their patients to maximize pharmacologic outcomes by avoiding these reported harmful interactions. (J Am Podiatr Med Assoc 99(1): 81–88, 2009)
advertising
